title: Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.
authors.affiliation: UC Davis Comprehensive Cancer Center, Sacramento, California.
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors.forename: Mary
authors.initials: M
authors.lastname: Redman
authors.affiliation: University of Colorado Cancer Center, Aurora.
authors.forename: Fred R
authors.initials: FR
authors.lastname: Hirsch
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D009154:Mutation
chemical_list: D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors